Harry Palmin
2020
In 2020, Harry Palmin earned a total compensation of $535.4K as Chief Operating Officer and Chief Financial Officer at Opexa Therapeutics, a 37% decrease compared to previous year.
Compensation breakdown
| Bonus | $152,960 |
|---|---|
| Salary | $382,400 |
| Total | $535,360 |
Palmin received $382.4K in salary, accounting for 71% of the total pay in 2020.
Palmin also received $153K in bonus.
Rankings
In 2020, Harry Palmin's compensation ranked 10,847th out of 13,090 executives tracked by ExecPay. In other words, Palmin earned more than 17.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,847 out of 13,090 | 17th |
Division Manufacturing | 4,634 out of 5,620 | 18th |
Major group Chemicals And Allied Products | 1,922 out of 2,253 | 15th |
Industry group Drugs | 1,685 out of 1,953 | 14th |
Industry Pharmaceutical Preparations | 1,243 out of 1,458 | 15th |
Source: SEC filing on April 16, 2021.
Palmin's colleagues
We found two more compensation records of executives who worked with Harry Palmin at Opexa Therapeutics in 2020.
News
Opexa Therapeutics CEO Chris Schelling's 2022 pay jumps 51% to $834K
April 14, 2023
Opexa Therapeutics Chief Business Officer Jefferson Davis receives $635K in 2021
April 15, 2022
Opexa Therapeutics CEO Chris Schelling's 2020 pay falls 54% to $676K
April 16, 2021
Opexa Therapeutics CEO Chris Schelling's 2019 pay jumps 167% to $1.5M
October 14, 2020
Opexa Therapeutics CEO Chris Schelling's 2018 pay slips 6% to $550K
April 12, 2019